US 12,226,452 B2
Polyhedrin-based slow release growth factor system for neuroprotection of retinal ganglion cell neurons
Julia Oswald Clifton, Medford, MA (US); Christian Pernstich, Cambridge (GB); Petr Baranov, Boston, MA (US); and Michael Jones, Royston (GB)
Assigned to The Schepens Eye Research Institute, Inc., Boston, MA (US); and Cell Guidance Systems Ltd, Cambridge (GB)
Filed by The Schepens Eye Research Institute, Inc., Boston, MA (US); and Cell Guidance Systems Ltd, Cambridge (GB)
Filed on Mar. 4, 2021, as Appl. No. 17/192,328.
Claims priority of provisional application 62/985,196, filed on Mar. 4, 2020.
Prior Publication US 2021/0275638 A1, Sep. 9, 2021
Int. Cl. A61K 38/18 (2006.01); A61P 27/06 (2006.01)
CPC A61K 38/185 (2013.01) [A61P 27/06 (2018.01)] 14 Claims
 
1. A method of treating glaucoma, Leber's hereditary optic neuropathy (LHON), toxic optic neuropathy, nonarteritic anterior ischaemic optic neuropathy (NAION), ischemic optic neuropathy, or retrograde degeneration associated with a pathology involving the Central Nervous System (CNS), the method comprising administering to an affected eye of a subject (a) a therapeutically effective amount of a composition comprising complexes of one or more growth factors attached to polyhedra comprising polyhedrin protein and (b) a population of donor retinal ganglion cells (RGCs).